Aldeyra Therapeutics

decision path change of plans arrows business decision

Biotech

Aldeyra drops and swaps RASP assets in response to data

Aldeyra stopped work on one asset in the wake of phase 2 data and swapped out two other molecules in response to recent results.

Nick Paul Taylor Oct 28, 2025 9:10am

eye eyeball eye art

Aldeyra posts hit, miss for dry eye drug, plans FDA filing

May 6, 2025 7:05am

Graphic image of a red thumbs down against a blue background

Aldeyra’s dry eye drug suffers second FDA rejection

Apr 3, 2025 8:46am

eye drops

Aldeyra preps for FDA refiling as dry eye drug hits ph. 3 goal

Aug 8, 2024 10:48am

graphic of a paper airplane labeled plan A crashing while a rocket labeled plan B takes off

Milestone resubmits NDA, Aldeyra readies 2nd chance filing

Mar 28, 2024 10:40am

bells new years christmas winter ring

ADC Tx, Aldeyra leave programs behind in 2023

Jan 4, 2024 10:05am